JAK2 inhibitorPhase 3 trialInvestigational
Fedratinib
How it works
Blocks the JAK2 enzyme, which is involved in signaling pathways that contribute to cancer growth.
Cancer types
Leukemia— All patients
Efficacy
Fedratinib has been shown to achieve a major cytogenetic response in around 30% of myeloproliferative neoplasm patients who have failed other therapies.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Fedratinib for Rare Blood Disorders: A Phase 2 Clinical Trial | Leukemia | phase-2 | — | Source → |
| JAK2 Inhibitor Shows Promise in Triple-Negative Breast Cancer | Breast Cancer | lab-study | Fedratinib significantly inhibited the proliferation of TNBC cells with IC values below 2 μM. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.